Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy - Publication - MOST Wiedzy

Search

Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy

Abstract

Citations

  • 7

    CrossRef

  • 6

    Web of Science

  • 8

    Scopus

Authors (15)

  • Photo of  Jan Walewski

    Jan Walewski

  • Photo of  Andrzej Hellmann

    Andrzej Hellmann

  • Photo of  Noppadol Siritanaratkul

    Noppadol Siritanaratkul

  • Photo of  Guner Ozsan

    Guner Ozsan

  • Photo of  Muhit Ozcan

    Muhit Ozcan

  • Photo of  Suporn Chuncharunee

    Suporn Chuncharunee

  • Photo of  Ai Goh

    Ai Goh

  • Photo of MD, PhD, Prof Wojciech Jurczak

    Wojciech Jurczak MD, PhD, Prof

  • Photo of  Jan Koren

    Jan Koren

  • Photo of  Ewa Paszkiewicz-Kozik

    Ewa Paszkiewicz-Kozik

  • Photo of  Bingxia Wang

    Bingxia Wang

  • Photo of  Shalini Singh

    Shalini Singh

  • Photo of  Dirk Huebner

    Dirk Huebner

  • Photo of  Andreas Engert

    Andreas Engert

  • Photo of  Bastian von

    Bastian von

Cite as

Full text

full text is not available in portal

Details

Category:
Magazine publication
Type:
Magazine publication
Published in:
BRITISH JOURNAL OF HAEMATOLOGY no. 183, edition 3, pages 400 - 410,
ISSN: 0007-1048
ISSN:
0007-1048
Publication year:
2018
DOI:
Digital Object Identifier (open in new tab) 10.1111/bjh.15539
Verified by:
No verification

seen 17 times

Meta Tags